Capreomycin sulfate (sterile) pharmaceutical-grade active pharmaceutical ingredient is a water-soluble cyclic polypeptide antibiotic complex isolated from Streptomyces capreolus. The complex comprises four components—capreomycin IA, IB, IIA, and IIB—with capreomycin IA and IB constituting the principal active fraction. The sulfate salt is identified by CAS 1405-37-4. The sterile grade is supplied as a white to off-white hygroscopic powder, freely soluble in water and practically insoluble in non-polar organic solvents. Manufacturer model designations may distinguish fill mass and container type; for example, a label code such as CAP-S-100G identifies a 100 g sterile powder aliquot in a Type I borosilicate glass vial, while CAP-S-500G identifies a 500 g aliquot. The pharmacopoeial identity and specification are not altered by fill-mass coding. The primary clinical use remains parenteral treatment of multidrug-resistant tuberculosis caused by Mycobacterium tuberculosis, in combination with additional second-line agents. Because the drug has very low oral absorption, tablet, capsule, and granule presentations are not regarded as therapeutically equivalent to the injectable route unless a specific bioavailability-enabling formulation is validated. The sterile API is a drug substance, not a ready-to-administer final drug product, and must be further processed under current good manufacturing practice.

What Process Risks Are Introduced When a Sterile Polypeptide API Is Transferred Across Solid Oral and Parenteral Formulation Trains?

The sterile API is sensitive to moisture, mechanical shear, and airborne contamination. In a parenteral line, final powder handling is performed in an isolator or restricted-access barrier system operating under Grade A/ISO 5 conditions with a Grade B/ISO 7 background, as described in EU GMP Annex 1 and ISO 14644-1:2015. If the same substance is moved to an oral solid-dosage pilot line, the non-sterile environment and high-shear granulation conditions can raise bioburden, increase water activity, and generate fines that alter blend homogeneity. The powder is hygroscopic; exposure to relative humidity above 60% may increase free moisture and accelerate hydrolysis. Operations should therefore include pre-drying or desiccated staging when ambient relative humidity exceeds 60%, and the powder should be returned to a sealed container with desiccant immediately after weighing. Water content is determined by USP 〈921〉 or Ph. Eur. 2.2.32. For parenteral processing, bacterial endotoxin limits are dose-based. Under USP 〈85〉 and Ph. Eur. 2.6.14, a 1 g daily dose in a 70 kg patient corresponds to an upper limit of approximately 0.35 EU/mg; release specifications are typically set at 0.10 EU/mg or 0.15 EU/mg to allow for downstream excipient and filling contribution. Because capreomycin sulfate in solution is heat-sensitive, terminal steam sterilization is generally avoided, and dry-heat sterilization is unsuitable for a peptide antibiotic. Published validation data for terminal moist-heat sterilization of this specific API are limited.

Batch-to-batch particle-size variation should be monitored with a laser diffraction instrument fitted with a dry dispersion unit, because wet dispersion can hydrate the powder and bias the result. Sieve fraction analysis may be used as a routine floor-level check, but laser diffraction is preferred for quantifying fines below 75 µm. In solid-dosage development, dry granulation by slugging or roller compaction is generally screened before aqueous wet granulation, because the combination of water, granulation shear, and drying heat can promote aggregation and impurity formation. Blend uniformity testing follows USP 〈905〉 for finished tablets or capsules; near-infrared monitoring may be used if a validated model is available. Equipment contact surfaces should be 316L stainless steel or inert polymeric material, and cleaning validation must address peptide residues because conventional alkaline cleaning agents may not fully remove adsorbed polypeptide material without a validated pre-rinse and detergent program.

Specification Architecture for Injectable-Grade Capreomycin Sulfate

The release specification is built from the current USP/NF capreomycin sulfate monograph, the Ph. Eur. monograph where applicable, WHO technical guidance for second-line tuberculosis drugs, ICH Q3C residual-solvent requirements, and ICH Q3D elemental-impurity requirements. Each lot is controlled for identity, potency, impurities, water content, solution clarity, sterility, bacterial endotoxins, residual solvents, and elemental impurities. Sterility is assessed according to USP 〈71〉 and Ph. Eur. 2.6.1. Particulate matter in the constituted injection is assessed by light obscuration under USP 〈788〉 or Ph. Eur. 2.9.19. The material is not released for parenteral compounding if sterility, endotoxin, particulate, or moisture results fall outside the approved limits.

For oral solid-dosage prototypes, the sterile API may be segregated into a dedicated non-sterile aliquot. This boundary is irreversible: once a batch or portion has entered non-aseptic granulation, blending, capsule-filling, or compression, it cannot be returned to injectable service. Facilities handling both routes should maintain separate containers, scoops, sampling devices, and weigh-booth liners for the sterile grade. Equipment cleaning and record-keeping should comply with 21 CFR 211.67 and 21 CFR 211.180. Cross-contact with aminoglycoside APIs must also be prevented because capreomycin and aminoglycosides may require separate residue limits and analytical methods.

When Oral Granule or Capsule Prototypes Are Commissioned Despite Low Enteric Permeability

Capreomycin sulfate is not an orally bioavailable antitubercular agent under conventional criteria. Current WHO treatment guidelines list capreomycin among injectable second-line agents; no harmonized oral monograph or BCS classification exists for this drug. Published human oral bioavailability data are limited. If a tablet, capsule, or granule program is initiated, it should be treated as an investigational delivery system rather than a compendial oral drug product. The main barriers are poor gastrointestinal permeability and potential instability in gastrointestinal fluid, not simply slow dissolution. Micronization or nanosuspension may increase dissolution rate, but it does not reliably overcome transport-limited absorption. Therefore, a plain oral tablet or capsule cannot be assumed to reproduce the parenteral therapeutic effect. Any in vitro dissolution method would require biorelevant media such as FaSSGF or FaSSIF and a Q-value justified by in vivo data; no harmonized pharmacopoeial dissolution acceptance criterion currently exists for oral capreomycin sulfate.

Granulation and compression conditions require special attention because the powder is hygroscopic and can stick to tooling. Dry granulation is preferred in early screening. If roller compaction is used, ribbon density, roll gap, and mill screen size should be evaluated against granule particle-size distribution and tablet content uniformity. Aqueous wet granulation should be avoided unless stability data demonstrate acceptable hydrolytic impurity formation. Capsule prototypes filled with the milled API may exhibit flow variability; direct encapsulation with a dosing disk or tamping pin system is more suitable than auger dosing if the powder has a broad particle-size distribution. These equipment-specific constraints are practical limits, not evidence of clinical oral efficacy.

Differences from Aminoglycoside and First-Line Antitubercular APIs in Solid and Parenteral Processing

Capreomycin sulfate is frequently grouped with amikacin and kanamycin in the injectable second-line class, but it is not an aminoglycoside. It is a cyclic polypeptide complex, and its degradation products, solution stability, and thermal sensitivity differ from aminoglycoside sulfates. In parenteral formulation, capreomycin sulfate is presented as a sterile powder for reconstitution; amikacin sulfate and streptomycin sulfate may be formulated as solutions or lyophilized powders, but their pH, osmolality, and excipient compatibility profiles differ. Capreomycin is not included in first-line fixed-dose combination tablets containing rifampicin, isoniazid, ethambutol, and pyrazinamide. The low oral permeability of capreomycin contrasts with rifampicin, pyrazinamide, ethambutol, and isoniazid, which are orally bioavailable and routinely processed by wet granulation or dry compression for fixed-dose combinations. For drug-susceptibility testing, capreomycin susceptibility should be determined by phenotypic methods such as CLSI M24-A2 or current WHO technical guidance, because cross-resistance with aminoglycosides is isolate-dependent and cannot be assumed from structural similarity alone.

Container closure systems for the sterile API are selected to prevent moisture ingress and maintain sterility during transport and storage. Elastomeric closures and vial seals should be evaluated for integrity under USP 〈1207〉 and for extractables and leachables under USP 〈1663〉 and USP 〈1664〉 when the API is intended for parenteral application. The sterile API is not intended for direct administration and must be further processed into a registered drug product under current GMP, with aseptic filtration or aseptic powder filling selected on the basis of a validated process risk assessment.